NIKKEI 225
40,946.69 +365.93 (+0.90%) HANG SENG
17,997.54 +18.97 (+0.11%) CRUDE OIL
83.30 -0.58 (-0.69%) GOLD FUTURES
2,369.40 0.00 (0.00%) DOW
39,308.00 -23.90 (-0.06%) Bitcoin GBP
46,163.39 -1,691.81 (-3.54%)
SMMT Aug 2024 7.000 call
- Business Wire
Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
MIAMI, July 03, 2024--Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") today announced the grant of inducement awards of options to purchase a collective total of up to 330,000 shares of common stock. Awards were made to six new employees of the Company. The awards were granted as an inducement material to the new employees becoming employees of the Company in accordance with Nasdaq Listing Rule 5635(c)(4) and have been approved by the Company’s Compensation Committee.
- Business Wire
Summit Therapeutics Appoints Jeff Huber, Transformational Google and GRAIL Executive, to its Board of Directors
MIAMI, June 27, 2024--Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") today announced that Jeff Huber has been appointed to its Board of Directors, effective immediately.
- Zacks
Summit (SMMT) Stock Surges 57% in the Past Month: Here's Why
Summit Therapeutics (SMMT) surges after data from a late-stage study shows that its experimental antibody beat Merck's Keytruda in a head-to-head setting in treating certain patients with lung cancer.
